Articles

Bolar and experimental use exemptions in the EU: how the landscape has changed for generic and biotech drug makers

Bolar and experimental use exemptions in the EU: how the landscape has changed for generic and biotech drug makers

Bolar and experimental use exemptions in the EU: how the landscape has changed for generic and biotech drug makers

17.12.2014 BE law

Team

Related news

23.02.2022 NL law
Courts take lenient approach to standing of ‘idealistic’ claim foundations under Dutch class action regime

Short Reads - Recent case law on the standing of ‘idealistic’ claim foundations shows courts’ lenient approach. Under the class action regime that entered into force in January 2020, claim foundations face stricter admissibility requirements as a counterbalance to their newly gained power to institute an opt-out damages claim. 

Read more